ReviewFrontiers in medicine2026
The role of mitochondrial dynamics in metabolic dysfunction-associated steatotic liver disease.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of manifestations arising from multisystem metabolic dysfunction impacting the liver. This spectrum includes hepatic conditions such as steatohepatitis, liver fibrosis, cirrhosis, and hepatic malignancies, as well as extrahepatic conditions like type 2 diabetes, atherosclerotic diseases, and chronic kidney diseases. MASLD has emerged as one of the most prevalent chronic liver diseases worldwide, characterized by a complex pathogenesis and a current lack of effective pharmacological interventions. With societal development and improved living standards, the incidence of MASLD is projected to rise, necessitating urgent research into its pathogenesis and the development of effective prevention and treatment strategies. Mitochondria, as the intracellular hubs of energy metabolism, are crucial in the onset and progression of MASLD through their dynamic processes. In recent years, the role of mitochondrial dynamics in the pathogenesis of MASLD has garnered increasing scholarly attention. This article provides a comprehensive overview of recent advancements in the relationship between mitochondrial dynamics and MASLD. It delves into the molecular mechanisms underlying mitochondrial fusion and fission, examines the functional abnormalities of mitochondrial dynamics in MASLD, and explores potential therapeutic strategies. These studies aim to offer novel insights and methodologies for the prevention and treatment of MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.